Pinealon

Pinealon (Glu-Asp-Arg; molecular weight 418.40) is a three-residue synthetic peptide developed at the St. Petersburg Institute of Bioregulation and Gerontology as a member of the Khavinson short-peptide bioregulator class. The compound is one of two Khavinson peptides explicitly targeted to pineal and central nervous system tissue (the other is Epitalon, Ala-Glu-Asp-Gly). The proposed mechanism is direct DNA binding at GC-rich promoter regions of pineal and neural tissue-specific genes, modulating transcription of melatonin biosynthetic enzymes, antioxidant defense genes, and neurotrophic factor genes; published Russian-language work characterizes binding to specific regulatory regions and effects on chromatin organization. Reported activities in rodent models include pro-cognitive effects in passive avoidance and Morris water maze paradigms, stress-protective activity, antioxidant elevation in cortex and hippocampus, and extension of mean lifespan in rodent aging studies. Routes studied include subcutaneous, intramuscular, and intranasal administration. The compound is registered in the Russian Federation as a research-grade tool peptide rather than a marketed medicine and is sold as a research-only preparation in some Western jurisdictions. The pharmacological profile shares features with Epitalon (the more extensively characterized pineal-targeting Khavinson peptide); investigators interested in pineal-targeted bioregulator research should consider both compounds. The principal limitation on the strength of the evidence is the dominance of the Khavinson laboratory's publications, the absence of independent Western replication of key longevity findings, and the limited mechanistic characterization at the molecular level beyond proposed DNA binding.